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Abstract
Background: The uptake of drugs into cells has traditionally been considered to be predominantly via passive
diffusion through the bilayer portion of the cell membrane. The recent recognition that drug uptake is mostly
carrier-mediated raises the question of which drugs use which carriers.
Results: To answer this, we have constructed a chemical genomics platform built upon the yeast gene deletion
collection, using competition experiments in batch fermenters and robotic automation of cytotoxicity screens,
including protection by ‘natural’ substrates. Using these, we tested 26 different drugs and identified the carriers
required for 18 of the drugs to gain entry into yeast cells.
Conclusions: As well as providing a useful platform technology, these results further substantiate the notion that
the cellular uptake of pharmaceutical drugs normally occurs via carrier-mediated transport and indicates that
establishing the identity and tissue distribution of such carriers should be a major consideration in the design of
safe and effective drugs.
Background
Of the many reasons for the attrition of candidate drugs
during the development process, toxicity or lack of efficacy
in vivo are among the most frequent [1,2]. Excessive con-
centration in particular tissues can be the cause of the for-
mer, while failure to reach targets can contribute to the
latter. The steady-state tissue distributions of drugs are
determined by the rates of their uptake and efflux. While
the role of carriers as mediators of drug efflux is well
appreciated, uptake was, until recently, considered to be
almost entirely a process of passive diffusion through the
lipid part of the membrane and therefore largely deter-
mined by drug lipophilicity, with carrier uptake considered
exceptional [3]. It is now increasingly recognized that drug
uptake is predominantly carrier-mediated [4-7]. The miss-
ing information required to understand the tissue distribu-
tions of drugs is thus represented by the specificities and
location of uptake carriers. Although there are any num-
ber of specific examples [6], the first task is to establish
general methods for determining which of the known
carriers are most responsible for the cellular uptake of par-
ticular drugs, as a prelude to establishing the tissue distri-
butions of the relevant carriers.
Saccharomyces cerevisiae is a well-understood and
widely used model organism for chemical genomics stu-
dies [8-12]. Existing data regarding the interaction of
yeast cells with drugs have brought up a number of cases
in which changes in the activity of specific carriers
increase or decrease the sensitivity of cells to xenobiotics,
with the clear implication that such carriers effect the
entry of these drugs into cells or their exit from them
[9,13-15]. A particular benefit of S. cerevisiae is the avail-
ability of a barcoded series of deletion mutants [16],
whose relative rates of growth/survival can be tested in
competition experiments (for examples, see [9,17-20]).
We therefore recognized that if a drug is toxic when pre-
sent at a high concentration inside the cell, but requires
the activity of a carrier to be taken up by the cell, a strain
with no or reduced carrier activity should be relatively
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experiments when compared to strains with normal
uptake activity. This analysis also predicts that if another
non-toxic (and possibly ‘natural’ [21]) substrate for the
carrier is known, then this will compete with the toxic
drug for uptake into the wild-type (WT) strain (assuming
equivalent binding sites), thereby conferring phenotypic
protection against toxicity.
I nt h ep r e s e n tw o r k ,w eh a v ee m p l o y e dt w oh i g h -
throughput platforms that exploit resistance associated
with gene deletion to identify drug transporters. We have
used these approaches to study the uptake of 26 pharma-
ceutically active (but - in yeast - cytotoxic) compounds.
The first platform consists of parallelized screens where
we grow the total pool of homozygous diploid yeast gene
deletants in batch fermenters, with and without the drug.
The proportions of the different strains in the population
are assayed by amplifying their molecular barcodes and
hybridizing them to a TAG4 oligonucleotide microarray.
Resistant strains will account for an increasing proportion
of the total pool in drug-treated compared to untreated
conditions, because they are able to outcompete suscepti-
ble strains due to the resistance conferred by the gene
deletion. The second platform screens strains individually
and relies upon robotics to increase throughput by spot-
ting strains deleted for genes encoding transporters onto
768-spot plates, allowing many strains to be screened in
parallel.
These high-throughput experiments suggested uptake
transporters for 18 of 26 compounds screened. For half of
the compounds with suggested transporters, validation
low-throughput experiments were performed confirming
most of the suggested transporters. Furthermore, protec-
tion experiments using known (‘native’)s u b s t r a t e sw e r e
performed for three of the drugs, confirming the role of
the suggested transporter in drug uptake.
Results
Canavanine transport: a proof-of-principle experiment
To calibrate and validate our experimental methods,
canavanine, a known antimetabolite substrate [22] of the
uptake transporter arginine permease (Can1p) was used.
Canavanine is an arginine analogue that is readily incor-
porated into proteins, producing a toxic effect. A concen-
tration of the drug was used that was sufficient to reduce
the growth rate of the WT strain by 90% (that is, the 90%
inhibitory concentration; IC90). Figure 1a shows results of
the pool experiment using canavanine, with resistance
associated with the can1Δ/can1Δ deletant demonstrated
by that strain’s top-ranked position on the drug-treated
axis. By plotting the mean arbitrary fluorescent units
from untreated and canavanine-treated pools, we could
clearly identify the can1Δ/can1Δ deletion strain as highly
enriched in the population following canavanine treat-
ment (Figure 1a).
In the robot-assisted experiments, four replicates of a
deletant strain for each of the known yeast genes encod-
ing transporter proteins were spotted onto solid med-
ium. Growth on a plate containing canavanine identified
only the known canavanine-resistant strain can1Δ/
can1Δ (data not shown), in complete agreement with
published data and with our results from the competi-
tion experiment described above.
We validated the results from both high-throughput
experiments by performing growth experiments in a
BioScreen C instrument (Thermo Electron, Helsinki, Fin-
land), which generates robust growth curves under more
strictly controlled conditions (Figure 1b). We calculated
the maximum growth rate of the WT and can1Δ/can1Δ
strains in the presence of canavanine (0 μMt o1 0 0μM;
Figure 1c), and confirmed that, unlike the wild type,
can1Δ/can1Δ mutants are insensitive to canavanine.
Furthermore, a competition experiment between canava-
nine and the native Can1p substrate, arginine, illustrates
the fully protective effect of arginine (Figures 1b and 1c).
Both of these results suggest that the cellular import of
canavanine occurs exclusively via Can1p, as reported
previously [23].
Drugs with a single protein carrier
The two screening procedures identified a number of
transporters which clearly represented the sole transporter
responsible for the uptake of a particular drug into yeast
cells. The first example is similar to that of Can1p trans-
porter and canavanine. We screened for transporters
responsible for the uptake of the anticancer drugs 5-fluor-
ocytosine and 5-fluorouracil and, as could have been
expected, found that the fcy2Δ/fcy2Δ mutant was the most
resistant strain (Additional Files 1 and 2). Fcy2p is a
known cytosine transporter and is so named because of
the fluorocytosine-resistant phenotype of its mutant alleles
[24].
The analysis of data from pool competition experiments
with diphenyleneiodonium chloride (DPI), by plotting the
mean arbitrary fluorescence of untreated and treated
pools, identified the nrt1Δ/nrt1Δ deletant as highly
enriched in the population following DPI treatment
(Figure 2a). Robot-assisted experiments using individual
transporter deletants spotted onto agar also identified
Nrt1p as the most likely DPI transporter (Figure 3). We
next performed growth assays on WT and nrt1Δ/nrt1Δ
strains in the presence of increasing DPI concentrations
and verified the resistance conferred by the deletion of the
candidate transporter (Figure S3a in Additional File 3).
DPI is an inhibitor of reduced nicotinamide adenine
dinucleotide phosphate oxidase and related enzymes
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Figure 1 Calibration and illustrative results from the pool competition approach. (a) Pool competition results for selection for canavanine
resistance. The abscissa indicates the proportion of each strain in the untreated pool. When treated (y-axis) the ability of the can1Δ/can1Δ diploid to
resist canavanine confers a major growth advantage to the strain such that it outcompetes all others to become the most abundant strain. Pink and
green lines (± 1000 y-translation of parity line) detail the boundary within which 98% of deletants are found when comparing untreated controls, so
providing a noise estimate. Indigo and cyan lines indicate treatment/control ratios of 2 and 3. Blue diamonds denote all deletants and black stars
identify strains deleted for transporter genes. AFU = mean arbitrary fluorescent units measured for the TAG4 arrays of treated (canavanine) and
untreated (control) competitions between the pools of homozygous deletants. (b) Growth curves of wild type (ydl227cΔ/ydl227cΔ)y e a s ts t r a i n si nt h e
presence of 10 μM of canavanine and increasing concentration of the competitor arginine. (c) Comparison of the maximum specific growth rate
achieved by the WT strain in the presence and absence of canavanine illustrates the cytotoxic effect of the drug. The protective effects of various
concentrations of arginine, one of the native substrates of Can1p, are shown over the drug concentration range (0 mM to 100 mM). A similar growth
rate advantage to deleting CAN1 is obtained by adding 250 μM of arginine. Error bars = standard error of the mean; n = 3.
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Figure 2 Competition experiment in the presence of diphenyleneiodonium chloride. (a) Pool competition results for selection for
diphenyleneiodonium chloride (DPI) resistance. The abscissa indicates the proportion of each strain in the untreated pool. When treated (y-axis)
the ability of the nrt1Δ/nrt1Δ diploid to resist DPI confers a major growth advantage to the strain such that it outcompetes all others to become
the most abundant strain. Green and blue lines (± 1000 y-translation of parity line) detail the boundary within which 98% of deletants are found
when comparing untreated controls, so providing a noise estimate. Blue diamonds denote all deletants and black stars identify strains deleted
for transporter genes. AFU = the mean arbitrary fluorescent units measured for the TAG4 Arrays of treated (DPI) and untreated (control)
competitions between the pools of homozygous deletants. (b) Comparison of the maximum specific growth rate achieved by wild type
(ydl227cΔ/ydl227cΔ) and nrt1Δ/nrt1Δ mutant in the presence of 0 to 20 μM DPI and 0 μMo r1 0μM of the competitor nicotinic acid. Error bars =
standard error of the mean; n = 3. DPI = diphenyliodonium chloride.
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mide riboside. Furthermore, both nicotinamide riboside
and thiamine [26] are known to be transported by
Nrt1p [27]. Therefore, we investigated whether the native
Nrt1p substrates could protect cells against DPI by out-
competing the drug for import via the Nrt1 transporter.
Nicotinamide riboside is not commercially available and
so the structurally related compounds, nicotinic acid and
nicotinamide, were assessed. We found that 10 μMo f
either nicotinic acid or nicotinamide protects against DPI
(at its IC90), recovering 80% of the control growth rate
(Figure 2b and data not shown). Thiamine, which is
i m p o r t e dv i aN r t 1 pw i t hal o w er affinity than nicotina-
mide riboside, was also able to protect cells against DPI,
albeit less efficiently than nicotinic acid (Figures S3b and
S3c in Additional file 3).
Using robot-assisted experiments, we found that two
structurally related antineoplastic drugs, methotrexate and
aminopterin, are also potential substrates of the Nrt1
transporter (Additional files 4 and 5). Neither nicotinic
acid nor nicotinamide protected against growth-rate inhi-
bition by methotrexate (data not shown). However, final
optical density (OD), which broadly equates to biomass
yield, can also indicate drug resistance. Using this as the
criterion, protection due to 10 μM nicotinamide or nicoti-
nic acid was observed, increasing the final OD from 0.3
without protection to 0.5 with the protective substrate
(compared to a final OD of 0.9 for the untreated wild
a b
cd
control
diphenyliodinium chloride (DPI)
identity
quantification
Figure 3 Identification of a putative diphenyleneiodonium chloride transporter in the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
dimethyl sulfoxide. (b) Identity of deletion mutants spotted onto control and drug plates. (c) Homozygous deletion mutant strains spotted in
quadruplicates (by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing 8 μM diphenyleneiodonium chloride. (d). Quantification
of the relative growth between drug and control plates with diphenyleneiodonium chloride resistant strains highlighted in green.
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trexate (data not shown).
Robot-assisted experiments also indicated an aminop-
terin resistance phenotype for the ctr1Δ/ctr1Δ (copper
transporter) and the fen2Δ/fen2Δ (pantothenate transpor-
ter) mutant strains (Additional file 5). Aminopterin inhi-
bits the activity of dihydrofolate reductase (DHFR), an
enzyme that is required for purine biosynthesis and for
which there is a high demand in rapidly growing cells [28].
Given that these two deletants have reduced growth rates
even in the absence of drugs (data not shown), it may be
that the consequent reduced demand for DHFR activity
m a k e st h e ml e s ss u s c e p t i b l et ot h ed e l e t e r i o u se f f e c t so f
DHFR inhibitors such as aminopterin.
Experiments with the alkylating agent iodoacetamide
[29] suggested a single transporter, the maltose transpor-
ter, Mal11p [30] (Additional file 6); however, this result
was only observed on solid medium and not in liquid cul-
tures. Furthermore, this drug/transporter combination
seems structurally improbable, and therefore needs to be
validated by independent methods to provide a clear pic-
ture of whether and how this import operates.
Robot-assisted experiments to identify the transporters
of Bay11-7085 (an NF-kappa B inhibitor) [31] and benz-
bromarone (the uricosuric agent used in the treatment of
gout) [32] suggested the uridine permease, Fui1p [33], as
the main route for cell entry (Additional Files 7 and 8).
However, due to the large number of suppressor mutants
of yeast plated on agar containing either of these two
drugs, this result could not be validated in liquid cultures.
While pool selections performed in the benzbromarone-
containing cultures did indicate that the fui1Δ/fui1Δ
mutant was among the five most enriched deletants in the
population, the enrichment measured was below our stan-
dard threshold of significance (data not shown).
Mitoxantrone is an antineoplastic agent that acts by
inhibiting Type II topoisomerases [34]. In robot-assisted
experiments, we found that the most likely route for
mitoxantrone to enter yeast cells is via the low-affinity
amino-acid permease, Agp1p [35] (Additional File 9).
Interestingly, the same route was suggested for protopor-
phyrin import (Additional file 10). Protoporphyrin is a tet-
rapyrrole used as a carrier for divalent cations [36] and it
has been previously suggested that it is imported into
yeast cells via Pug1p [37]. However, in our strain back-
ground and experimental conditions (robot-assisted
experiments), pug1Δ/pug1Δ mutants were not phenotypi-
cally different from the control strains (Additional file 10).
Drugs for which multiple transporters were identified
Quantitative analysis of the robot-assisted experiments per-
formed on cisplatin plates identified the purine and cyto-
sine permease, Fcy2p [24], as the main import route for
this anticancer drug (Additional File 11). The experiments
also identified the phospholipid transporter, Lem3p [38], as
a putative cisplatin transporter; however, this was not
reproduced in liquid cultures. Interestingly, the arsenite
and antimonite transporter, Fps1p, as well as the choline/
ethanolamine transporter, Hnm1p, also showed resistance
to cisplatin, albeit to a level below our threshold of 3 SD
from the plate average (Additional File 12). As with many
of the examples in this section, experiments with double
(in this case, fps1Δ hnm1Δ) or multiple mutants might
reveal a very strong resistance phenotype and establish the
relative contribution of each of the carrier proteins to the
transport of the drug.
Tunicamycin is an antibiotic that inhibits protein N-
glycosylation [39] and therefore is used experimentally to
induce the unfolded protein response [40]. Robot-assisted
experiments on tunicamycin plates identified five trans-
porter gene deletions conferring resistance to the drug:
lem3Δ/lem3Δ, dnf2Δ/dnf2Δ, pca1Δ/pca1Δ, pho89Δ/
pho89Δ and qdr2Δ/qdr2Δ (Additional File 13). Both
L e m 3 pa n dD n f 2 pa r ep h o s p h o lipid transporters [38,41]
and therefore might contribute to tunicamycin import by
binding the hydrophobic tail common to all forms of the
drug (Additional file 14). Pho89p and Pca1p are phos-
phate [42] and metal transporters [43], respectively, and
therefore are unlikely to be responsible for the direct
uptake of the drug. Qdr2p, on the other hand, is a known
pleiotropic drug transporter that might well assist in
tunicamycin import [44]. More examples of the indirect
effect of transporters on drug uptake or efficacy are given
below.
Drugs for which transporters have an indirect effect on
their efficacy
Robot-assisted experiments linked the Fcy2p transporter
(required for the import of 5-fluorocytosine and 5-fluorur-
acil, see above) to the import of the antifungal drug, fluco-
nazole (Additional File 15). Deletions of three additional
transporter genes (FET3, FTR1, and ITR1) also conferred
resistance to fluconazole. Fluconazole acts by inhibiting
the cytochrome P450 enzyme 14-a-demethylase [45], one
of only three P450s in S. cerevisiae. Cytochrome P450s are
heme-containing proteins, and Fet3p and Ftr1p are known
iron import routes [46,47]. Therefore, it is plausible that
the resistance to fluconazole that we observed with fet3Δ/
fet3Δ and ftr1Δ/ftr1Δ mutants might be an influence on
the drug’s target, rather than its import. Itr1p is a myoino-
sitol transporter and its role in fluconazole import is not
clear [48]. Interestingly, robot-assisted experiments also
identified Itr1p as the putative transporter of two more
azole antifungal drugs, ketoconazole (80 μM) and clotri-
mazole (32 μM) (Additional Files 16 and 17), which also
target the cytochrome P450 family. This result establishes
a new link between Itr1p and azoles. At lower clotrimazole
concentrations (25 μM), fet3Δ/fet3Δ and ftr1Δ/ftr1Δ
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18).
Robot-assisted experiments on cantharidin (a drug used
for the topical treatment of warts and other skin tumors)
identified no transporter deletion strain that showed resis-
tance to the drug at a significance level above our standard
threshold of 3 SD over the plate average (data not shown).
However, if we lowered the stringency of the screen to
include hits 2.5 SD above the plate average (Additional
File 19), we could identify Snq2p, Cch1p, Mid1p, Pho89p
or Fen2p as possible uptake routes. Snq2p is a multidrug
transporter and therefore a plausible cantharidin import
route [49]. Cch1p and Mid1p work together to mediate
calcium import [50]. Whilst it is reassuring to identify two
proteins that are known to work in tandem, it seems unli-
kely that calcium channels are directly responsible for
cantharidin import. Pho89p is responsible for phosphate
uptake and cantharidin is a phosphatase inhibitor [42,51].
Therefore, we might infer that a phosphate imbalance due
to the pho89Δ/pho89Δ mutation might be responsible for
the observed resistance and that Pho89p is not directly
responsible for cantharidin uptake. The structure of
cantharidin does not resemble known Fen2p substrates
(tail of two carbons and a carboxyl group; Additional file
20); however, validation assays in liquid cultures verified
the resistance to cantharidin observed in fen2Δ/fen2Δ
strains (data not shown).
Robot-assisted experiments with the antimalarial drug,
artesunate [52], did not provide strong hits using the sig-
nificance threshold of 3 SD above the plate average (data
not shown). However, when looking for the strains with
growth 2 SD above the plate average, we identified cch1Δ/
cch1Δ [50], mid1Δ/mid1Δ [50] and fen2Δ/fen2Δ as artesu-
nate-resistant strains (Additional File 21). The overlap
between the cantharidin and artesunate hits is quite strik-
ing; especially considering that cantharidin has also been
demonstrated to be an antiparasitic (antileishmanial) agent
[53]. After drug-induced cell stress, yeast cells frequently
undergo changes in intracellular calcium concentrations
mediated by Cch1p-Mid1p [54], therefore the role of
cch1Δ/cch1Δ and mid1Δ/mid1Δ deletions in resistance to
artesunate and cantharidin is unlikely to be due to a direct
role in drug import. However, the pantothenate transpor-
ter Fen2p is a possible artesunate import route as it bears
the carboxyl tail observed in other Fen2p substrates (ami-
nopterin and pantothenate) and in the substrates of
related proteins, Vht1p and Dal5p (Additional File 20)
[55,56].
The drug 1,10-phenanthroline is a heterocyclic organic
compound that forms strong complexes with most metal
ions [57]. Interestingly, robot-assisted experiments using
this drug suggested the high-affinity copper transporter,
Ctr1p [58], as the major route of cellular ingress for
phenanthroline (Additional file 22). It remains to be
demonstrated if phenanthroline import is aided by the for-
mation of a complex with copper or if the resistance we
observed is an indirect effect of an intracellular copper
imbalance (we observed that strains lacking the iron trans-
porters Ftr1p [47] or Fet3p [46] are hypersensitive to phe-
nanthroline). Ammonium pyrrolidine dithiocarbamate is a
metal chelator that induces G1 cell cycle arrest [59].
Therefore, it was not surprising to identify the strain lack-
ing the cadmium transporter, Pca1p, as the most resistant
strain in a robot-assisted experiment (Additional File 23).
The 1,10-phenanthroline resistance observed in a pca1Δ/
pca1Δ strain could be due to an indirect effect caused by
metal imbalance and not by a direct role of Pca1p in drug
import.
Drugs for which no transporter could be identified
At the concentrations tested (Table 1 and data not
shown), we could not identify candidate transporters for
3,4-dichloroisocoumarin, N-phenylanthranilic acid,
tamoxifen, tetraethylthiur a md i s u l p h i d e( t h ea l c o h o l
deterrent, disulfiram), vanillylmandelic acid (the tyrosine
mono-oxygenase inhibitor, metyrosine) or ZM39923 (the
Janus kinase inhibitor). With our current experimental
set-up, it is not possible to determine whether this was
due to passive diffusion of the drug via the plasma mem-
brane, presence of multiple transporters equally capable
of importing the drugs (in which case, only double
mutants would show adequate resistance to the drug) or
whether the strain deleted for the correct transporter was
not present in our collection. Even if no transporter is
present in S. cerevisiae, the possibility that human cells
may contain specific transporters for these drugs cannot
be excluded, since bioinformatic analyses predict that the
human genome encodes 1022 transporter proteins, com-
pared with yeast’s 318 [60].
Discussion
The importance of carriers in drug uptake has, until
recently, been much overlooked in favor of the idea of
drug uptake by diffusion through the lipid bilayer, despite
persuasive arguments and extensive evidence to the con-
trary [60-65]. Carriers are an important component of cel-
lular biochemistry (and of biotechnological production
[66]), with many hundreds known in both yeast [67] and
human [68,69] cells. To assess which drugs use which
transporters, we have employed two high-throughput
experimental platforms to identify new drug-transporter
interactions. Through these targeted validation experi-
ments, including protection with known substrates, we
have been able to identify and/or confirm the transporters
required for uptake of 18 of 26 drugs tested (Table 1).
The approach we have described relies on substrates
being cytotoxic, and upon the identification of the opti-
mum drug concentration for each screen. Furthermore,
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single deletion mutants, we would not always be able to
detect redundant transporters. Therefore, a collection
with double transport mutants would provide invaluable
information about possible transporters for those drugs
not yielding hits.
For hundreds of transporters to mediate the uptake of
tens of thousands of diverse compounds, as must occur if
transporters dominate uptake, considerable transporter
promiscuity is required. Certain solute carriers present in
mammalian genomes are known to transport extremely
diverse substrates, with PepT1 being a particularly clear
example for which early structure-activity relationships
have been defined [70]. Yet such structural insights are
exceptional and, generally, the chemical basis of
promiscuous transporter function is not well understood.
Here, we have identified several examples of yeast trans-
porters with multiple and diverse substrates. Fen2p has
been shown to mediate the uptake of artesunate, pan-
tothenate and aminopterin, which bear the characteristic
carboxyl group of other Fen2p substrates and the sub-
strates of related transporters (Dal5p: allantoate, ureido-
succinate; Vht1p: biotin), but are otherwise structurally
dissimilar. Our experiments also link 5-fluorouracil and
cantharidin to Fen2p, which do not bear the carboxyl
group. This suggests Fen2p might transport an even
broader range of substrates, although we cannot elimi-
nate the possibility that the gene deletion confers resis-
tance indirectly (as indeed is the case for fenpropimorph,
after which the protein is named).
Table 1 Summary of the transporters responsible for the uptake of cytotoxic drugs
Drug Pool
hits
Robot
[μM]
Robot hits Indirect effect Verification hits Competitor Lipinski’s
Rules [3]
Aminopterin 2 nrt1Δ, fen2Δ ctr1Δ nrt1Δ,c tr1Δ NT Fail
Amm. pyrrolidine
thiocarbamate
20 pca1Δ NT NT Pass
Artesunate 100 fen2Δ (2*s) cch1Δ, mid1Δ (2*s) NT NT Pass
Bay 11-7985 10 fui1Δ NT NT Pass
Benzbromarone None 28 fui1Δ NT NT Fail
Canavanine can1Δ 5 can1Δ can1Δ pass Fail
Cantharidin 30 fen2Δ, snq2Δ (2.5*s) cch1Δ, mid1Δ, pho89Δ
(2.5*s)
fen2Δ pho89Δ (others
NT)
NT Pass
Cisplatin 50 fcy2Δ, lem3Δ, (fat1Δ, fps1Δ,
hnm1Δ 2*s)
fcy2Δ, (fat1Δ, fps1Δ,
hnm1Δ NT)
NT Pass
Clotrimazole 25 itr1Δ ftr1Δ fet3Δ NT NT Fail
3,4-Dichloroisocoumarin 8 None Pass
Diphenyleneiodonium
chloride
nrt1Δ 8 nrt1 nrt1Δ pass Pass
Fluconazole 100 itr1Δ fcy2Δ ftr1Δ fet3Δ NT NT Pass
5-Fluorocytosine 158 fcy2 fcy2Δ NT Pass
5-Fluorouracil 158 fcy2Δ fen2Δ fcy2Δ fen2 NT Pass
Iodoacetamide 20 mal11Δ (2.5*s) Reproducible only on
solid
NT Pass
Ketoconazole 80 itr1Δ fat1Δ NT NT Fail
Methotrexate 100 nrt1Δ nrt1Δ pass Fail
Mitoxantrone 75 agp1 NT NT Fail
1,10-Phenanthroline 14 ctr1Δ NT NT Pass
N-Phenylanthranilic Acid 100 None Pass
Protoporphyrin 600 agp1Δ NT NT Fail
Tamoxifen 730 None Fail
Tetraethylthiuram
disulfide
10 pdr5Δ (2*s) NT NT Fail
Tunicamycin 4 lem3Δ dnf2Δ qdr2Δ pca1Δ pho89Δ all confirmed NT Fail
Vanillylmandelic acid 647 None Pass
ZM 39923 14 None Fail
NT indicates liquid verification or competitor experiments were not tested.
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between drugs and transporters that are difficult to ratio-
nalize, as well as links with tantalizing (but far from con-
clusive) structural similarities - such as that between
benzbromarone and the uridine substrate of Fui1p. This
lack of a substrate-level understanding of transporter func-
tion particularly highlights the need for methods such as
those developed here, which are capable of uncovering
links one would not otherwise anticipate. It seems clear,
however, that, in combination, a set of transporters are
indeed capable of the promiscuity necessary to mediate
the uptake of very diverse substrates.
Drug development is a multi-objective optimization task,
with major components of the objective function being
terms describing the pharmacokinetic processes of drug
absorption, tissue distribution and excretion, all of which
involve uptake across cellular membranes. To understand
pharmacokinetics properly and mechanistically, therefore,
requires knowledge of the interactions between transpor-
ters (including genetic variants) and their substrates (pri-
marily drugs, nutrients, and endogenous metabolites).
Allelic variation data based on the knowledge of these car-
riers will feed into structure-activity relationship modeling
to allow the prediction of likely substrates from large drug
libraries [21], and into integrative systems biology models
[71] using a patient’s individual genotype to move towards
delivering personalized medicine.
Conclusions
This work has exploited the gene-deletion collection of the
model eukaryote, S. cerevisiae, to employ two chemical
genomics platforms with which to identify drug carriers
responsible for the uptake of a range of very diverse com-
pounds. The first involves competition between deletion
mutants in liquid culture, while the second uses a robot to
seed arrays of mutants on agar - in both systems the
impact of drugs on the mutants’ growth may readily be
measured and the genes specifying drug carriers identified
by the drug resistance of their cognate deletion mutants.
In this way, we have provisionally identified the protein
carriers mediating the entry, into yeast, of 18 of 26 drugs
studied. Moreover, the impact of the deletion mutants on
drug entry firmly establishes that transport via protein car-
riers, rather than simple diffusion, is likely to be the main
route of cellular ingress for many drugs.
Methods
Strains and culture conditions
The homozygous deletion pool and individual homozy-
gous and heterozygous deletion strains used were gener-
ated in the S. cerevisiae deletion project [16]. The
parental strain Y23935 (MATa/a his3Δ1/his3Δ1l e u 2 Δ0/
leu2Δ0l y s 2 Δ0/LYS2 MET15/met15Δ0u r a 3 Δ0/ura3Δ0
ydl227c::kanMX4/YDL227c) was used as the WT control
throughout (referred to as the WT or standard strain).
YDL227c is the open reading-frame of the HO gene,
which is not expressed in diploid cells; its deletion has no
measurable effect on growth rate. Strains were routinely
grown in F1 minimal medium [45,46] containing 0.5%
glucose as the carbon source or 2% glucose for the robot-
generated arrays (Additional file 24). Strains were main-
tained on 2% yeast extract peptone dextrose (YPD) agar,
supplemented with 200 mg/L of Geneticin (G-418;
Sigma, Sigma-Aldrich, Gilligham, Dorset, UK). Minimal
medium without non-essential amino acids was used
throughout growth experiments to minimize possible
competition of drug uptake with natural substrates.
BIOSCREEN experiments and drug screening
Strains were grown on a BIOSCREEN C (distributed by
Thermo Electron) in triplicate in a total assay volume of
300 μL at 30°C with intensive on/off shaking [47]. The OD
was measured at 600 nm every 10 minutes. For initial
screening to determine cytotoxicity, strains were chal-
lenged with drugs from the Library of Pharmacologically
Active Compounds (LOPAC; Sigma-Aldrich, Dorset, UK)
and National Cancer Institute (NCI) Mechanistic and
Diversity sets http://dtp.nci.nih.gov/index.html. The maxi-
mum final concentration of a dimethyl sulfoxide (DMSO)
solution of a drug tested was 100 μM for LOPAC and NCI
Diversity sets, and 10 μM for the NCI Mechanistic set,
since final DMSO concentrations of > 1% (v/v) reduced
the maximum specific growth rate of S. cerevisiae signifi-
cantly (data not shown).
Pool experiments
Pool experiments were performed as 1.2-liter batch fer-
mentations using the homozygous deletant pool. The dele-
tant pool was stored at -80°C and 200 μL was inoculated
into 50 mL F1 medium (0.5% glucose) and incubated on a
rotary shaker at 30°C overnight (12 hours). The overnight
culture was harvested by centrifugation and the pellet
resuspended in 50 mL of fresh F1 medium. Twelve millili-
ters (1% final concentration) of inoculum were injected
into a 1200 mL aerated (1 gas volume flow per unit of
liquid volume per minute (vvm)), stirred (700 rpm) and
heated (30°C) Applikon 1030 bioreactor (FT Applikon
Ltd., Tewkesbury, UK) with a 2.3 L full working volume.
The pH was kept constant at 4.5 using 1M potassium
hydroxide.
Prior to inoculation, drug solutions were added to the
fermenter at their IC90 concentrations. In the control,
untreated cells grew under equivalent culture conditions.
For this type of experiment, overall runtime is not a com-
parative measure because the strains in the population
each respond differently to drug treatment. Accordingly,
the final sample was taken when the OD measurement
indicated the transition from the exponential growth
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drop in carbon dioxide (CO2) evolution. Growth and the
end-point of growth were monitored using OD600 and
CO2 evolution, measured online via an external CO2 gas
analyzer (Tandem Gas analyzer, Magellan Instruments,
Lipenhoe, UK). Cells were harvested by centrifugation
and the pellets stored at -80°C prior to analysis.
DNA extraction, TAG4 array hybridization
DNA extraction, polymerase chain reactions, TAG4
array hybridization and data analysis were performed
according to the methods of Pierce and co-workers [72]
using their normalization protocol.
Preparation of the master-plates for the robot-assisted
experiments
Yeast strains with deletions of 111 genes encoding
plasma membrane transporters http://http:\\www.yeast-
genome.org, as well as multiple copies of the WT control
strain [KanMX deletion cassette in the HO (YDL227c)
locus] were inoculated into 70 μL of YPD in duplicate in
a 384-well plate (master-plate). Where possible the
homozygous mutants were used, but in the case of the
essential genes VHT1 (YGR065c), YPP1 (YGR198w) and
ALR1 (YOL130w); or when homozygous deletion strains
were not available in our strain collection [STE6
(YKL209c)], the corresponding heterozygous strain was
used instead. To minimize problems with edge effect, we
placed WT strains on all the border wells of our master
plates. The master-plate was incubated at 30°C for 36
hours to ensure that each strain had grown to the sta-
tionary phase, in order to homogenize the growth
throughout the plate.
Drug selection and preparation of the test-plates
We selected 26 compounds cytotoxic in yeast, 14 of which
pass the Lipinski’s rule of five (all compounds were pur-
chased from Sigma). Stock solutions of each drug were
prepared in water, ethanol or DMSO (according to the
compound solubility). Adequate volumes of these stock
solutions were added to 40 mL of F1 minimal media to
make plates with the final drug concentrations indicated
in Table 1. For the stock solutions in DMSO, the concen-
tration of the solvent in the final plate was never greater
than 1% by volume, since high DMSO concentrations
affect yeast growth (data not shown). The cultures in the
384-well master-plate were spotted in duplicate onto the
plates using a Singer RoToR
© HAD (Singer Instrument
Co., Watchet, Somerset, UK) robot to generate a test plate
with 768 spots, that is, each mutant in quadruplicate. The
cells were allowed to grow for at least 48 hours at 30°C,
at which point images of the plates were captured on
the standard gel documentation system, Gel Doc 2000
(Bio-Rad, Bio-Rad UK Ltd, Hemel Hempstead, UK), and
saved as JPEG images.
Quantification of growth on robot generated plates
The quantification of yeast growth on robot-generated
plates was based on the method described in Bilsland et
al. [73], with a few modifications to account for the num-
ber of colonies on each plate. MATLAB was used to con-
vert the JPEG images to three-dimensional intensity
matrices, and the intensities from the blue channel were
used to quantify the colony sizes. The corners of the plate
were identified manually and, accordingly, a ‘window size’
was calculated as the larger of the following two values:
the width of the image divided by the number of columns
or length of the image divided by the number of rows.
The image was then partitioned into equal-sized diamond-
shaped windows, with diagonals the same length as the
‘window size’ calculated previously, and each window
framing a colony. The pixels with intensity 25% higher
than the minimum intensityo ft h ec o l o n yw i n d o ww e r e
counted and the total count was assigned as the size of the
colony.
The colonies on the edges of the plates, the WT buffer,
were excluded from further analysis as the sizes of these
colonies are biased by ‘edge effects’ (the decreased compe-
tition resulting from being on the edge). For the four spots
corresponding to each particular mutant, the median size
was calculated. Because the strains did not all grow at the
same rate on control plates, this median value was then
divided by the median value of the four spots of the corre-
sponding mutant on the relevant control plate. Finally,
this value was multiplied by 100. Strains with sizes more
than 2.5 SD below the plate average were highlighted red,
signifying sensitivity, and strains with sizes more than 3
SD above the plate average were highlighted green, signify-
ing resistance. In some cases, the threshold for resistance
was lowered to 2.5 or 2 SD, in order to compensate for
the effects of extreme outliers on the average value.
Additional material
Additional file 1: Identification of a putative 5-fluorocytosine
transporter by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
158 μM 5-fluorocytosine. (d) Quantification of the relative growth
between drug and control plates with 5-fluorocytosine resistant strains
highlighted in green.
Additional file 2: Identification of a putative 5-fluorouracil
transporter by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 agar medium containing 1% DMSO.
(b) Identity of deletion mutants spotted onto control and drug plates.
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Page 10 of 14(c). Homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 158
μM 5-fluorouracil. (d) Quantification of the relative growth between drug
and control plates with 5-fluorouracil resistant strains highlighted in
green.
Additional file 3: Validation of Nrt1p as the main DPI transporter.
(a) Growth curves of wild type (ydl227cΔ/ydl227cΔ) and nrt1Δ/nrt1Δ yeast
strains in the presence of various DPI concentrations. (b) Comparison of
the maximum specific growth rate achieved by the WT strain in the
presence of various concentrations of DPI and the competitor nicotinic
acid. (c) Comparison of the maximum specific growth rate achieved by
the WT strain in the presence of various concentrations of DPI and the
competitor thiamine. Error bars = standard error of the mean; n = 3.
Additional file 4: Identification of putative methotrexate
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
100 μM methotrexate. (d) Quantification of the relative growth between
drug and control plates with methotrexate resistant strains highlighted in
green.
Additional file 5: Identification of putative aminopterin transporters
by the robot-assisted experiment. (a) Control plate with homozygous
deletion mutant strains spotted in quadruplicates (by a Singer RoToR
©
HAD robot) onto F1 medium agar plate containing 1% DMSO. (b)
Identity of deletion mutants spotted onto control and drug plates. (c)
Homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 2 μM
aminopterin. (d) Quantification of the relative growth between drug and
control plates with aminopterin resistant strains highlighted in green.
Additional file 6: Identification of a putative iodoacetamide
transporter by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
20 μM iodoacetamide. (d) Quantification of the relative growth between
drug and control plates with iodoacetamide resistant strains highlighted
in green.
Additional file 7: Identification of putative Bay11-7085 transporters
by the robot-assisted experiment. (a) Control plate with homozygous
deletion mutant strains spotted in quadruplicates (by a Singer RoToR
©
HAD robot) onto F1 medium agar plate containing 1% DMSO. (b)
Identity of deletion mutants spotted onto control and drug plates. (c)
Homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 10 μM
Bay11-7085. (d) Quantification of the relative growth between drug and
control plates with Bay11-7085 resistant strains highlighted in green.
Additional file 8: Identification of putative benzbromarone
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
2 μM benzbromarone. (d) Quantification of the relative growth between
drug and control plates with benzbromarone resistant strains highlighted
in green.
Additional file 9: Identification of putative mitoxantrone
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
75 μM mitoxantrone. (d) Quantification of the relative growth between
drug and control plates with mitoxantrone resistant strains highlighted in
green.
Additional file 10: Identification of putative protoporphyrin
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
600 μM protoporphyrin. (d) Quantification of the relative growth
between drug and control plates with protoporphyrin resistant strains
highlighted in green.
Additional file 11: Identification of putative cisplatin transporters
by the robot-assisted experiment. (a) Control plate with homozygous
deletion mutant strains spotted in quadruplicates (by a Singer RoToR
©
HAD robot) onto F1 medium agar plate. (b) Identity of deletion mutants
spotted onto control and drug plates. (c) Homozygous deletion mutant
strains spotted in quadruplicates (by a Singer RoToR
© HAD robot) onto
F1 medium agar plate containing 50 μM cisplatin. (d) Quantification of
the relative growth between drug and control plates with cisplatin
resistant strains highlighted in green (3 SD above the plate average).
Additional file 12: Identification of putative cisplatin transporters
by the robot-assisted experiment. (a) Control plate with homozygous
deletion mutant strains spotted in quadruplicates (by a Singer RoToR
©
HAD robot) onto F1 medium agar plate containing 1% DMSO. (b)
Identity of deletion mutants spotted onto control and drug plates. (c)
Homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 50 μM
cisplatin. (d) Quantification of the relative growth between drug and
control plates with cisplatin resistant strains highlighted in green (2 SD
above the plate average).
Additional file 13: Identification of putative tunicamycin
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
4 μM tunicamycin. (d) Quantification of the relative growth between
drug and control plates with tunicamycin resistant strains highlighted in
green.
Additional file 14: Chemical structure of tunicamycin linked to the
proposed transporters.
Additional file 15: Identification of putative fluconazole transporters
by the robot-assisted experiment. (a) Control plate with homozygous
deletion mutant strains spotted in quadruplicates (by a Singer RoToR
©
HAD robot) onto F1 medium agar plate containing 1% DMSO. (b)
Identity of deletion mutants spotted onto control and drug plates. (c)
Homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 100
μM fluconazole. (d) Quantification of the relative growth between drug
and control plates with fluconazole resistant strains highlighted in green.
Additional file 16: Identification of putative ketoconazole
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
80 μM ketoconazole. (d) Quantification of the relative growth between
drug and control plates with ketoconazole resistant strains highlighted in
green.
Additional file 17: Identification of putative clotrimazole
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
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Page 11 of 14plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
32 μM clotrimazole. (d) Quantification of the relative growth between
drug and control plates with clotrimazole resistant strains highlighted in
green.
Additional file 18: Identification of putative clotrimazole
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
25 μM clotrimazole. (d) Quantification of the relative growth between
drug and control plates with clotrimazole resistant strains highlighted in
green.
Additional file 19: Identification of putative cantharidin transporters
by the robot-assisted experiment. (a) Control plate with homozygous
deletion mutant strains spotted in quadruplicates (by a Singer RoToR
©
HAD robot) onto F1 medium agar plate containing 1% DMSO. (b)
Identity of deletion mutants spotted onto control and drug plates. (c)
Homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 30 μM
cantharidin. (d) Quantification of the relative growth between drug and
control plates with cantharidin resistant strains highlighted in green (2.5
standard deviations above the plate average).
Additional file 20: Chemical structures of cantharidin, artesunate
and aminopterin as well as that of the native substrate carried by
the proposed transporter, Fen2p.
Additional file 21: Identification of putative artesunate transporters
by the robot-assisted experiment. (a) Control plate with homozygous
deletion mutant strains spotted in quadruplicates (by a Singer RoToR
©
HAD robot) onto F1 medium agar plate containing 1% DMSO. (b.
Identity of deletion mutants spotted onto control and drug plates. (c)
Homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 100
μM artesunate. (d) Quantification of the relative growth between drug
and control plates with artesunate resistant strains highlighted in green
(2 SD above the plate average).
Additional file 22: Identification of putative 1,10-phenanthroline
transporters by the robot-assisted experiment. (a) Control plate with
homozygous deletion mutant strains spotted in quadruplicates (by a
Singer RoToR
© HAD robot) onto F1 medium agar plate containing 1%
DMSO. (b) Identity of deletion mutants spotted onto control and drug
plates. (c) Homozygous deletion mutant strains spotted in quadruplicates
(by a Singer RoToR
© HAD robot) onto F1 medium agar plate containing
14 μM 1,10-phenanthroline. (d) Quantification of the relative growth
between drug and control plates with 1,10-phenanthroline resistant
strains highlighted in green.
Additional file 23: Identification of putative ammonium pyrrolidine
dithiocarbamate transporters by the robot-assisted experiment. (a)
Control plate with homozygous deletion mutant strains spotted in
quadruplicates (by a Singer RoToR
© HAD robot) onto F1 medium agar
plate containing 1% DMSO. (b) Identity of deletion mutants spotted
onto control and drug plates. (c) Homozygous deletion mutant strains
spotted in quadruplicates (by a Singer RoToR
© HAD robot) onto F1
medium agar plate containing 20 μM ammonium pyrrolidine
dithiocarbamate. (d) Quantification of the relative growth between drug
and control plates with ammonium pyrrolidine dithiocarbamate resistant
strains highlighted in green.
Additional file 24: F1 minimal medium. Components I, II and III can be
made up together at 5× final concentration and autoclaved. Component
III can be made up at 5× final concentration and autoclaved.
Component IV (vitamin solution) is filter-sterilized and kept at -20°C;
aliquots are added to fresh 1× solution. Component V is made up as
40% w/v stock solution and autoclaved.
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